Circulating tumor cells: Exploring intratumor heterogeneity of colorectal cancer

Cancer Biology and Therapy

Volumn 15, Issue 5, 2014, Pages 496-503

  Raimondi, Cristina ^a   Nicolazzo, Chiara ^a   Gradilone, Angela ^a   Giannini, Giuseppe ^a   De Falco, Elena ^a   Chimenti, Isotta ^a   Varriale, Elisa ^b   Hauch, Siegfried ^c   Plappert, Linda ^c   Cortesi, Enrico ^a   Gazzaniga, Paola ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Diachem Srl   (Italy)

^c Adnagen GmbH   (Germany)

Author keywords

Biomarker; Circulating tumor cells; Colorectal cancer; KRAS; Tumor heterogeneity

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; K RAS PROTEIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ARTICLE; CELL ISOLATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CODON; COLORECTAL CANCER; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; METASTATIC COLORECTAL CANCER; MUTATION; ONCOGENE; POINT MUTATION; SEQUENCE ANALYSIS; TRANSCRIPTION INITIATION; AGED; COLORECTAL TUMOR; FEMALE; GENETICS; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR EMBOLISM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84899850606     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28020     Document Type: Article

References (37)

1. Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Target Oncol 2013; 8:83-96; PMID:23645285; http://dx.doi.org/10.1007/s11523-013-0281-x
2. Newton KF, Newman W, Hill J. Review of biomarkers in colorectal cancer. Colorectal Dis 2012; 14:3-17; PMID:21040359; http://dx.doi.org/10.1111/j.1463- 1318.2010.02439.x
3. Jancík S, Drábek J, Radzioch D, Hajdúch M. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010; 2010:150960; PMID:20617134; http://dx.doi.org/10.1155/2010/150960
4. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486:532-6; PMID:22722830
5. Berg M, Soreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med 2012; 14:207-14; PMID:23021375
6. Yang ZY, Wu XY, Huang YF, Di MY, Zheng DY, Chen JZ, Ding H, Mao C, Tang JL. Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis. Int J Cancer 2013; 133:1914-25; PMID:23494461; http://dx.doi.org/10.1002/ijc.28153
7. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res 2012; 72:4875-82; PMID:23002210; http://dx.doi.org/10.1158/0008-5472. CAN-12-2217
8. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013; 108:479-85; PMID:23299535; http://dx.doi.org/10.1038/bjc.2012.581
9. Alix-Panabières C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59:110-8; PMID:23014601; http://dx.doi.org/10. 1373/clinchem.2012.194258
10. Miller MC, Doyle GV, Terstappen LW. Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol 2010; 2010:617421; PMID:20016752; http://dx.doi.org/10.1155/2010/617421
11. Tol J, Koopman M, Miller MC, Tibbe A, Cats A, Creemers GJ, Vos AH, Nagtegaal ID, Terstappen LW, Punt CJ. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 2010; 21:1006-12; PMID:19861577; http://dx.doi.org/10.1093/annonc/mdp463
12. Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, et al. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. Oncologist 2012; 17:947-55; PMID:22643538; http://dx.doi.org/10.1634/theoncologist.2012-0048
13. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 2009; 20:1223-9; PMID:19282466; http://dx.doi.org/10.1093/annonc/mdn786
14. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:3213-21; PMID:18591556; http://dx.doi.org/10.1200/JCO.2007.15.8923
15. Bidard FC, Ferrand FR, Huguet F, Hammel P, Louvet C, Malka D, Boige V, Ducreux M, Andre T, de Gramont A, et al. Disseminated and circulating tumor cells in gastrointestinal oncology. Crit Rev Oncol Hematol 2012; 82:103-15; PMID:21680197; http://dx.doi.org/10.1016/j.critrevonc.2011.05.008
16. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol 2009; 6:519-27; PMID:19636327; http://dx.doi.org/10.1038/ nrclinonc.2009.111
17. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12:594-603; PMID:21163703; http://dx.doi.org/10.1016/S1470-2045(10)70209-6
18. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, et al. Multideterminants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009; 4:e7287; http://dx.doi.org/10.1371/journal.pone.0007287; PMID:19806185
19. Mekenkamp LJ, Tol J, Dijkstra JR, de Krijger I, Vink- Börger ME, van Vliet S, Teerenstra S, Kamping E, Verwiel E, Koopman M, et al. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer 2012; 12:292; PMID:22804917; http://dx.doi.org/10.1186/1471-2407-12-292
20. Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, et al. KRAS gene amplification in colorectal cancer and impact on response to EGFRtargeted therapy. Int J Cancer 2013; 133:1259-65; PMID:23404247; http://dx.doi.org/10. 1002/ijc.28106
21. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013; 8:277-302; PMID:23092187; http://dx.doi.org/10.1146/annurev-pathol-020712-163923
22. Marusyk A, Polyak K. Cancer. Cancer cell phenotypes, in fifty shades of grey. Science 2013; 339:528-9; PMID:23372002; http://dx.doi.org/10.1126/science. 1234415
23. Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M. Characterization of metastatic breast cancer patients with nondetecTable 3irculating tumor cells. Int J Cancer 2011; 129:417-23; PMID:20857493; http://dx.doi.org/10.1002/ijc.25690
24. Gazzaniga P, Raimondi C, Gradilone A, Di Seri M, Longo F, Cortesi E, Frati L. Circulating tumor cells, colon cancer and bevacizumab: the meaning of zero. Ann Oncol 2011; 22:1929-30; PMID:21633048; http://dx.doi.org/10.1093/ annonc/mdr292
25. Miyazono K. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci 2009; 85:314-23; PMID:19838011; http://dx.doi.org/10.2183/pjab. 85.314
26. Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, Wierinckx A, Devouassoux- Shisheboran M, Treilleux I, Tissier A, Gras B, et al. EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice. PLoS Genet 2012; 8:e1002723; http://dx.doi.org/10.1371/journal.pgen.1002723; PMID:22654675
27. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Colon Cancer Version 2. 2013
28. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16:790-9; PMID:20103678; http://dx.doi.org/10.1158/1078-0432.CCR-09-2446
29. Knijn N, Mekenkamp LJ, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, van Krieken JH, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104:1020-6; PMID:21364579; http://dx.doi.org/10.1038/bjc.2011.26
30. Yen LC, Yeh YS, Chen CW, Wang HM, Tsai HL, Lu CY, Chang YT, Chu KS, Lin SR, Wang JY. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2009; 15:4508-13; PMID:19549774; http://dx.doi.org/10.1158/1078-0432.CCR-08-3179
31. Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, Mauermann O, Izbicki JR, Pantel K, Riethdorf S. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem 2013; 59:252-60; PMID:23136247; http://dx.doi.org/10.1373/clinchem.2012.188557
32. Mostert B, Jiang Y, Sieuwerts AM, Wang H, Bolt-de Vries J, Biermann K, Kraan J, Lalmahomed Z, van Galen A, de Weerd V, et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 2013; 133:130-41; PMID:23233388; http://dx.doi.org/10.1002/ijc.27987
33. Fabbri F, Carloni S, Zoli W, Ulivi P, Gallerani G, Fici P, Chiadini E, Passardi A, Frassineti GL, Ragazzini A, et al. Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. Cancer Lett 2013; 335:225-31; PMID:23419522; http://dx.doi.org/10.1016/j.canlet.2013.02.015
34. Parsons BL, Myers MB. Personalized cancer treatment and the myth of KRAS wild-type colon tumors. Discov Med 2013; 15:259-67; PMID:23636143
35. Zeng M, Kikuchi H, Pino MS, Chung DC. Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. PLoS One 2010; 5:e10966; http://dx.doi.org/10.1371/journal.pone.0010966; PMID:20532039
36. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304:1812-20; PMID:20978259; http://dx.doi.org/10.1001/jama.2010.1535
37. Lankiewicz S, Zimmermann S, Hollmann C, Hillemann T, Greten TF. Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer. Mol Oncol 2008; 2:349-55; PMID:19383356; http://dx.doi.org/10.1016/j.molonc.2008.09.001